Neurizon Therapeutics Limited has released a press release.
Strategy for Phase II Clinical Trial of Monepantel
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Appendix 4D & Half Yearly Report and Accounts
- Notice of Allowance received from USA Patent OffIce
- Treatment of Canine Cancers
- SPP Shortfall Heaily Oversubscribed
- Share Sale Deed executed for the sale of Pela Resources
Later from Neurizon Therapeutics
- Appendix 4C Quarterly & Company Update
- Clinical Trial in Dogs is now open for accrual
- Human Cancer Trial Advancing To Second Patient
- Appendix 4C
- Appendix 4C - Quarterly
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics